Abstract
The amyloid β-peptide (Aβ) plays an early and critical role in the pathogenic cascade leading to Alzheimers disease (AD). Aβ is typically found in extracellular amyloid plaques that occur in specific brain regions in the AD and Down syndrome brain. Mounting evidence, however, indicates that intraneuronal accumulation of this peptide may also contribute to the cascade of neurodegenerative events that occur in AD and Down syndrome. A pathogenic role for intracellular Aβ is not without precedent, as it is known to be an early and integral component of the human muscle disorder inclusion body myositis (IBM). Therefore, it is plausible that intracellular Aβ may likewise induce cytopathic effects in the CNS, causing neuronal and synaptic dysfunction and perhaps even neuronal loss. Here we review recent evidence supporting a pathogenic role for intracellular Aβ in AD, Down syndrome, and IBM.
Keywords: parkinsons disease, amyotrophic lateral sclerosis, amyloid plaques, inclusion body myositis, alzheimers disease, paired helical filaments, brain
Current Alzheimer Research
Title: Amyloid β-Peptide: The Inside Story
Volume: 1 Issue: 4
Author(s): Bertrand P. Tseng, Masashi Kitazawa and Frank M. LaFerla
Affiliation:
Keywords: parkinsons disease, amyotrophic lateral sclerosis, amyloid plaques, inclusion body myositis, alzheimers disease, paired helical filaments, brain
Abstract: The amyloid β-peptide (Aβ) plays an early and critical role in the pathogenic cascade leading to Alzheimers disease (AD). Aβ is typically found in extracellular amyloid plaques that occur in specific brain regions in the AD and Down syndrome brain. Mounting evidence, however, indicates that intraneuronal accumulation of this peptide may also contribute to the cascade of neurodegenerative events that occur in AD and Down syndrome. A pathogenic role for intracellular Aβ is not without precedent, as it is known to be an early and integral component of the human muscle disorder inclusion body myositis (IBM). Therefore, it is plausible that intracellular Aβ may likewise induce cytopathic effects in the CNS, causing neuronal and synaptic dysfunction and perhaps even neuronal loss. Here we review recent evidence supporting a pathogenic role for intracellular Aβ in AD, Down syndrome, and IBM.
Export Options
About this article
Cite this article as:
Tseng P. Bertrand, Kitazawa Masashi and LaFerla M. Frank, Amyloid β-Peptide: The Inside Story, Current Alzheimer Research 2004; 1 (4) . https://dx.doi.org/10.2174/1567205043332045
DOI https://dx.doi.org/10.2174/1567205043332045 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immune Mediated Necrotizing Myopathy: Where do we Stand?
Current Rheumatology Reviews Tubulin-Independent Tau in Alzheimer’s Disease and Cancer: Implications for Disease Pathogenesis and Treatment
Current Alzheimer Research Endoplasmic Reticulum Stress, Calcium Dysregulation and Altered Protein Translation: Intersection of Processes That Contribute to Cancer Cachexia Induced Skeletal Muscle Wasting
Current Drug Targets Subcutaneous Immunoglobulins: A Promising Alternative for Immunomodulation?
Current Pharmaceutical Design Autoimmune Neuromuscular Disorders
Current Neuropharmacology New Drugs for Immune Targeting
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Interstitial Lung Disease Associated with Collagen Vascular Disease
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Aspartic Proteases in Drug Discovery
Current Pharmaceutical Design Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease
Current Pharmaceutical Design Targeting Vascular Disease in Systemic Sclerosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Simvastatin: Review of Updates on Recent Trends in Pharmacokinetics, Pharmacodynamics, Drug–drug Interaction, Impurities and Analytical Methods
Current Pharmaceutical Analysis Topical Applications of Ozone and Ozonated Oils as Anti-Infective Agents: An Insight into the Patent Claims
Recent Patents on Anti-Infective Drug Discovery The Proteasome in Health and Disease
Current Pharmaceutical Design Perioperative/Periprocedural Effects of Statin Treatment for Patients Undergoing Vascular Surgery or Endovascular Procedures: An Update
Current Vascular Pharmacology Biomarkers of Subclinical Atherosclerosis and Natural Products as Complementary Alternative Medicine
Current Pharmaceutical Design Modulation and Detection of Tau Aggregation with Small-Molecule Ligands
Current Alzheimer Research ADAM19/Adamalysin 19 Structure, Function, and Role as a Putative Target in Tumors and Inflammatory Diseases
Current Pharmaceutical Design Formaldehyde as a trigger for protein aggregation and potential target for mitigation of age-related, progressive cognitive impairment
Current Topics in Medicinal Chemistry The Immune Response to the Parasitic Nematode Trichinella and the Ways to Escape it. From Experimental Studies to Implications for Human Infection.
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Impact of Immunosuppressive Drugs on the Development of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology